USING INSULIN ON DIABETES INPATIENTS AT THE INTERNAL MEDICINE DEPARTMENT OF CAN THO UNIVERSITY OF MEDICINE AND PHARMACY HOSPITAL IN 2017-2020

Quang Loc Duyen Vo 1,, Thi My Duyen Huynh1
1 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Background: Diabetes is a dangerous chronic medical condition with a rapid increasing rate of hospitalization and a high mortality ratio. Insulin is the most important drugs in diabetes medications for inpatients. Therefore, using insulin in a reasonable, safe and effective manner is always a matter of concern. Objectives: To determine the characteristics of using insulin on treating for diabetes inpatients. Materials and methods: A cross-sectional descriptive study was conducted on 390 medical records of diabetes inpatients who were treated at The Internal Medicine Department of Can Tho University of Medicine and Pharmacy Hospital in 2017-2020. Results: The rate of insulin monotherapy was 73.3%. In the group of insulin and oral diabetes medications, the insulin combination with metformin and DPP4i was 13.1%. The mixture insulin was accounted for 77.5%. The rate of 2 doses premixed insulin per day was 95.9%. The average of insulin dose was 23.4 ± 10.6 UI per day. There were 6 turns of insulin regimens change in treatment process and the total insulin dose on the first day of using new regimen was unequal with the total insulin dose on the final day of using previous regimen, with the ratio was 83.4%. Conclusions: The selection of using insulin on diabetes inpatients is suitable with world guidelines and the reality situation of hospital.

Article Details

References

1. Bùi Tùng Hiệp (2014), Khảo sát các yếu tố ảnh hưởng đến kết quả điều trị đái tháo đường týp 2 tại Khoa nội tiết Bệnh viện cấp cứu Trưng Vương Thành phố Hồ Chí Minh, Tạp chí y học TP.HCM, 18(3), tr 89-93.
2. Nguyễn Thanh Truyền (2019), Nghiên cứu tình hình kiểm soát đường huyết ở bệnh nhân đái tháo đường type 2 điều trị nội trú bằng insulin tại Bệnh viện đa khoa thành phố Cần Thơ, Luận văn chuyên khoa cấp 2, Trường Đại học Y Dược Cần Thơ.
3. American Diabetes Association (2019), “Standards of Medical Care in Diabetes - 2019", Diabetes Care, 42(1), pp. S1-S193.
4. Chentli F., Azzoug S. (2015), “Diabetes mellitus in elderly”, Indian journal of endocrinology and metabolism, 19(6), pp. 744.
5. Farshchi A., Aghili R. (2016), “Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study”, BMC endocrine disorders, 16(1), pp. 1-9.
6. Frid A. H., Hirsch L. J. (2016), “Worldwide injection technique questionnaire study: population parameters and injection practices”, Mayo Clinic Proceedings, 91(9), pp. 1212-1223.
7. International Diabetes Federation (2019), IDF Diabetes Atlas: Ninth edition, pp. 1-168.
8. Kautzky‐Willer A., Kosi L., (2016), “Gender‐based differences in glycaemic control and hypoglycaemia prevalence in patients with type 2 diabetes: results from patient‐level pooled data of six randomized controlled trials”, Diabetes, obesity and metabolism, 17(6), pp. 533-540.
9. Kodner C., Anderson L. (2017), “Glucose management in hospitalized patients”, American family physician, 96(10), pp. 648-654.
10. Ong KY, YH Kwan (2015), “Prevalence of dysglycaemic events among inpatients with diabetes mellitus: a Singaporean perspective”, Singapore medical journal, 56(7), pp. 393-400.
11. Palta P., Huang E. S. (2017), “Hemoglobin A1c and mortality in older adults with and without diabetes: results from the National Health and Nutrition Examination Surveys (1988–2011)”, Diabetes Care, 40(4), pp. 453-460.
12. Schutta M. H. (2007), “Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions”, Journal of the cardiometabolic syndrome, 2(2), pp. 124-130.
13. Therapeutic Research Center (2009), "How to switch insulin products", Pharmacist’s letter, 25, pp. 1- 4.
14. Umpierrez G. E., Pasquel F. J. (2017), “Management of inpatient hyperglycemia and diabetes in older adults”, Diabetes care, 40(4), pp. 509-517.
15. Vilsbøll T., Rosenstock J. (2010), “Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes”, Diabetes, Obesity and Metabolism, 12(2), pp. 167-177.